Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression
The Lancet Infectious Diseases, 08/21/2012
Kalil AC et al. – Real–life use of drotrecrogin alfa (activated) was associated with significant reduction in hospital mortality and increased rates of bleeding in patients with severe sepsis. The effectiveness findings were in line with the PROWESS trial but not with the PROWESS–SHOCK trial.